Andrés Redondo

14.8k total citations · 1 hit paper
199 papers, 3.3k citations indexed

About

Andrés Redondo is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrés Redondo has authored 199 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 78 papers in Reproductive Medicine and 68 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrés Redondo's work include Ovarian cancer diagnosis and treatment (76 papers), Sarcoma Diagnosis and Treatment (41 papers) and PARP inhibition in cancer therapy (39 papers). Andrés Redondo is often cited by papers focused on Ovarian cancer diagnosis and treatment (76 papers), Sarcoma Diagnosis and Treatment (41 papers) and PARP inhibition in cancer therapy (39 papers). Andrés Redondo collaborates with scholars based in Spain, United States and Italy. Andrés Redondo's co-authors include Phillip J. Sheridan, Roy S. Rogers, David Hardisson, Marta Mendiola, Enrique Espinosa, Jorge Barriuso, Juan Ángel Fresno Vara, Steven E Eckert, Paloma Cejas and Manuel González-Barón and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Andrés Redondo

178 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023

2023 85 citations Sven Mahner, Mansoor Raza Mirza et al. International Journal of Gynecological Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrés Redondo Spain	28	1.0k	895	559	550	548	199	3.3k
Jae Wook Kim South Korea	31	446 0.4×	951 1.1×	501 0.9×	719 1.3×	342 0.6×	129	2.9k
Hao Lin Taiwan	28	389 0.4×	722 0.8×	529 0.9×	333 0.6×	577 1.1×	228	3.2k
Ofer Nativ Israel	35	388 0.4×	1.0k 1.1×	158 0.3×	332 0.6×	1.3k 2.3×	187	3.9k
Sang‐Yoon Park South Korea	34	810 0.8×	906 1.0×	1.3k 2.3×	379 0.7×	313 0.6×	197	3.7k
Corrado Rubini Italy	40	1.7k 1.7×	2.4k 2.7×	58 0.1×	997 1.8×	660 1.2×	261	6.2k
A. Ayhan Türkiye	40	1.2k 1.1×	1.7k 1.9×	2.2k 4.0×	713 1.3×	683 1.2×	224	5.3k
Linda Sugar Canada	37	418 0.4×	1.3k 1.4×	121 0.2×	856 1.6×	1.7k 3.0×	93	3.8k
Juri Kopolovic Israel	43	672 0.7×	1.6k 1.8×	637 1.1×	513 0.9×	456 0.8×	137	5.5k
G. Bastert Germany	37	2.8k 2.8×	1.0k 1.2×	154 0.3×	1.1k 2.0×	790 1.4×	216	5.3k
Shin Nieh Taiwan	30	646 0.6×	951 1.1×	43 0.1×	404 0.7×	223 0.4×	102	2.3k

Countries citing papers authored by Andrés Redondo

Since Specialization

Citations

This map shows the geographic impact of Andrés Redondo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Redondo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Redondo more than expected).

Fields of papers citing papers by Andrés Redondo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Redondo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Redondo. The network helps show where Andrés Redondo may publish in the future.

Co-authorship network of co-authors of Andrés Redondo

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Redondo. A scholar is included among the top collaborators of Andrés Redondo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Redondo. Andrés Redondo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Robert F., Jubilee Brown, JW Kim, et al.. (2025). 69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results. ESMO Open. 10. 105199–105199.

López‐Janeiro, Álvaro, Ignacio Ruz‐Caracuel, Carlos E. de Andrea, et al.. (2025). The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas. Cells. 14(21). 1676–1676.

Mendiola, Marta, Victoria Heredia-Soto, Ignacio Ruz‐Caracuel, et al.. (2024). Performance of the Idylla microsatellite instability test in endometrial cancer. Molecular and Cellular Probes. 77. 101976–101976.

Palmerini, Emanuela, Antonio López–Pousa, Giovanni Grignani, et al.. (2024). Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial. Cancer. 131(1). e35628–e35628. 6 indexed citations

Mendiola, Marta, Jani Saarela, Victoria Heredia-Soto, et al.. (2024). Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma. Biomedicine & Pharmacotherapy. 173. 116397–116397. 1 indexed citations

Marmé, Frederik, Philipp Harter, Andrés Redondo, et al.. (2024). Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.. Journal of Clinical Oncology. 42(17_suppl). LBA5501–LBA5501. 9 indexed citations

Noti, Luca, José A. Galván, Inti Zlobec, et al.. (2023). Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. Frontiers in Medicine. 10. 1110529–1110529.

Pérez, M.J. Rubio, Florian Heitz, R D Christensen, et al.. (2023). LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial. Annals of Oncology. 34. S1278–S1279. 6 indexed citations

Martín‐Broto, Javier, Kateřina Kopečková, Ignacio Azinovic, et al.. (2023). 1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study. Annals of Oncology. 34. S1035–S1036. 1 indexed citations

10.

Redondo, Andrés, Maria-Pilar Barretina-Ginesta, José Alejandro Pérez Fidalgo, María Jesús Rubio, & Antonio González-Martı́n. (2023). Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. Journal of Gynecologic Oncology. 34(5). e57–e57. 2 indexed citations

11.

Spagnolo, Emanuela, Alejandra Martínez, Josep Marí‐Alexandre, et al.. (2023). Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features. International Journal of Molecular Sciences. 24(15). 12083–12083. 1 indexed citations

12.

Gallego, Alejandro, Marta Mendiola, Bárbara Hernando, et al.. (2022). Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. International Journal of Gynecological Cancer. 32(8). 1009–1016. 10 indexed citations

13.

Ruz‐Caracuel, Ignacio, Victoria Heredia-Soto, Bulat Zagidullin, et al.. (2022). Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. Cancers. 14(4). 912–912. 5 indexed citations

14.

Mirza, Mansoor Raza, Gabriel Lindahl, Sven Mahner, et al.. (2022). Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Research Communications. 2(11). 1436–1444. 5 indexed citations

15.

Martín‐Broto, Javier, Andrés Redondo, David S. Moura, et al.. (2022). A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 13(1). 6278–6278. 2 indexed citations

16.

López‐Janeiro, Álvaro, Ignacio Ruz‐Caracuel, Vivian de los Rı́os, et al.. (2021). Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Cancers. 13(4). 794–794. 36 indexed citations

17.

Ruz‐Caracuel, Ignacio, Álvaro López‐Janeiro, Laura Yébenes, et al.. (2019). Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. Cancers. 11(12). 1845–1845. 20 indexed citations

18.

Alemany, Regina, David S. Moura, Andrés Redondo, et al.. (2018). Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research. 24(21). 5239–5249. 22 indexed citations

19.

Redondo, Andrés, Manuel Ramos Vázquez, Luís Manso, et al.. (2018). Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets and Therapy. Volume 11. 5845–5852. 5 indexed citations

20.

Campo, J.L. & Andrés Redondo. (1997). The relationship of brown deposits in the eggs with stress, fear and shell quality. Archiv für Geflügelkunde. 61(6). 267–269. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact